强生泛FGFR抑制剂厄达替尼国内获批上市;全球第2款PROTAC药物进入III期阶段

Ofweek光电信息网
14 Jan

强生国内新动态。1月13日,强生宣布,FGFR抑制剂厄达替尼片获NMPA批准上市,用于治疗携带易感型FGFR3基因变异,且既往接受至少一线含抗PD-1或抗PD-L1期间或之后出现疾病进展的手术不可切除的局部晚期或转移性尿路上皮癌成人患者。百时美施贵宝又有新动作。日前,据Clinicaltrials官网,百时美施贵宝子公司Celgene启动了BMS-986365的首个III期临床试验。这是全球第2款...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10